What is Zacks Research's Forecast for IRWD FY2024 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research report issued on Thursday, November 28th. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings of $0.08 per share for the year, down from their previous estimate of $0.14. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.08 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.17 EPS and Q3 2026 earnings at $0.13 EPS.

IRWD has been the subject of a number of other reports. Craig Hallum dropped their target price on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating for the company in a report on Friday, August 9th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a "hold" rating in a research report on Monday, September 9th. StockNews.com downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, November 12th. Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a "market perform" rating and a $5.00 price target on the stock. Finally, Capital One Financial lowered shares of Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $10.40.

Ironwood Pharmaceuticals Price Performance

IRWD traded up $0.10 during trading on Monday, hitting $3.62. 1,399,831 shares of the stock traded hands, compared to its average volume of 2,864,204. The firm has a market capitalization of $579.31 million, a P/E ratio of -120.67 and a beta of 0.47. Ironwood Pharmaceuticals has a 12-month low of $3.26 and a 12-month high of $15.70. The firm has a 50-day moving average of $4.11 and a 200 day moving average of $5.16.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. Ironwood Pharmaceuticals's revenue was down 19.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.12 earnings per share.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in Ironwood Pharmaceuticals in the 3rd quarter worth about $78,000. Vestcor Inc raised its holdings in Ironwood Pharmaceuticals by 37.8% in the third quarter. Vestcor Inc now owns 159,466 shares of the biotechnology company's stock worth $657,000 after buying an additional 43,703 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Ironwood Pharmaceuticals by 102.7% in the third quarter. Jane Street Group LLC now owns 323,638 shares of the biotechnology company's stock worth $1,333,000 after buying an additional 164,006 shares in the last quarter. Wolverine Trading LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the third quarter valued at approximately $51,000. Finally, Weiss Asset Management LP bought a new stake in shares of Ironwood Pharmaceuticals during the third quarter valued at approximately $893,000.

Insider Buying and Selling at Ironwood Pharmaceuticals

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares of the company's stock, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.90% of the company's stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.